知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.019 seconds)

    VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
    2.
    发明申请
    VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER 审中-公开

    公开(公告)号：US20170112929A1

    公开(公告)日：2017-04-27

    申请号：US15174213

    申请日：2016-06-06

    Applicant: KINGS COLLEGE LONDON ,  THE TRUSTEES OF DARTMOUTH COLLEGE

    Inventor： Randolph NOELLE

    IPC: A61K39/395 ,  A61K45/06 ,  C12N15/113 ,  C07K16/28 ,  A61K39/00

    Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

    Therapeutic Aryl-Amido-Aryl Compounds and Their Use
    3.
    发明申请
    Therapeutic Aryl-Amido-Aryl Compounds and Their Use 有权
    治疗性芳酰胺基芳基化合物及其用途

    公开(公告)号：US20160039747A1

    公开(公告)日：2016-02-11

    申请号：US14879340

    申请日：2015-10-09

    Applicant: Kings College London

    Inventor： Jonathan Patrick Thomas Corcoran ,  Sarkis Barret Kalindjian ,  Alan David Borthwick ,  David Reginald Adams ,  Jane Theresa Brown ,  David Michel Adrien Taddei ,  Jason John Shiers

    IPC: C07C235/84

    CPC classification number: C07C235/84 ,  C07C233/75 ,  C07C235/56 ,  C07C237/42 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D213/30 ,  C07D213/80 ,  C07D213/81 ,  C07D237/24

    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

    Abstract translation: 本发明一般涉及治疗化合物的领域，更具体地涉及以下式的某些芳基 - 酰氨基 - 芳基化合物（为了方便起见，统称为“AAA化合物”），其特别是（选择性的 ）视黄酸受体α（RARα）激动剂。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途（选择性地）激活RARα，以及在治疗由RARα介导的疾病和病症中的应用， 通过RARα等的激活改善，包括认知障碍，记忆障碍，记忆缺陷，老年痴呆，阿尔茨海默病，早期阿尔茨海默氏病，中期阿尔茨海默病，晚期阿尔茨海默氏病，认知障碍和轻度认知障碍。

    Prevention of uveitis
    5.
    发明申请
    Prevention of uveitis 审中-公开
    预防葡萄膜炎

    公开(公告)号：US20040265341A1

    公开(公告)日：2004-12-30

    申请号：US10751106

    申请日：2004-01-05

    Applicant: Kings College London

    Inventor： Thomas Lehner ,  Miles R. Stanford

    IPC: A61K039/02 ,  C07K014/28

    CPC classification number: C07K14/28 ,  A61K39/00 ,  C07K14/315 ,  C07K2319/00

    Abstract: A conjugate with recombinant cholera toxin B sub-unit (rCTB) of a peptide or polypeptide consisting of or containing a sequence corresponding to amino acid residues 336-351 of the human heat shock protein HSP 60, or the corresponding residues of the microbial 65 kD heat shock protein, or one which differs from either of these by up to and including 4 amino acid alterations (sub-situation and/or deletion and/or insertion) and having similar tolerising properties for Behcet's disease, or related types of uveitis, by oral, nasal, transmucosal or parenteral administration, or one which is extended from any one of the above-mentioned residues at the N-terminus or C-terminus or both with one or more non-wild-type amino acid sequences.

    Abstract translation: 由与热休克蛋白HSP60的氨基酸残基336-351相对应或含有对应于微生物65kD的相应残基的序列的肽或多肽的重组霍乱毒素B亚单元（rCTB）的缀合物 热休克蛋白，或其中任何一种不同于直到并包括4个氨基酸改变（子情况和/或缺失和/或插入）并且具有类似的白塞病或相关类型的葡萄膜炎的耐受性，通过 口服，鼻腔，经粘膜或非肠道给药，或从N末端或C末端的任一个上述残基延伸的两个或两个以上的非野生型氨基酸序列。

    METHOD AND SYSTEM TO ASSIST 2D-3D IMAGE REGISTRATION
    8.
    发明申请
    METHOD AND SYSTEM TO ASSIST 2D-3D IMAGE REGISTRATION 有权
    辅助2D-3D图像注册的方法和系统

    公开(公告)号：US20150043798A1

    公开(公告)日：2015-02-12

    申请号：US14382999

    申请日：2013-03-01

    Applicant: Kings College London ,  Guy's & St. Thomas' NHS Foundation Trust

    Inventor： Tom Carrell ,  Andreas Varnavas ,  Graeme Penney

    IPC: G06T7/00

    CPC classification number: G06T7/0012 ,  A61B6/5223 ,  G06T7/73 ,  G06T2207/10064 ,  G06T2207/10081 ,  G06T2207/30012

    Abstract: Embodiments of the invention provide a system and method that is able to automatically provide a starting point for 2D to 3D image registration, without relying on human recognition of features shown in the 2D image. This is achieved by pre-processing the 3D data to obtain synthetically generated 2D images of those parts of the 3D data volume which will be used for registration purposes. Many different synthetically generated 2D images of the or each part of the 3D volume are produced, each from a different possible viewing direction. Each of these synthetic images is then subject to a feature extraction process to extract characterising feature data of the registration feature shown in the images. Once the feature extraction has been undertaken for each image, when registration is to be performed the real-time 2D image is processed by applying each of the sets of extracted features thereto, to try and identify which set best matches the registration features in the 2D image. For example, where a generalised Hough transform was used in the feature extraction, the R tables would be applied to the 2D image to obtain respective accumulation images. The accumulation images may then be ranked to identify which registration feature is shown in the 2-D image, and from which view direction. This gives the required information of which registration feature is being shown in the 2D image, and also the in-plane location and orientation. This information can then be used as a starting point for the 2D to 3D registration procedure.

    Abstract translation: 本发明的实施例提供了一种系统和方法，其能够自动地提供用于2D到3D图像配准的起始点，而不依赖于对2D图像中所示的特征的人类识别。 这是通过预处理3D数据来获得将用于注册目的的3D数据卷的那些部分的合成生成的2D图像来实现的。 产生3D体积或每个部分的许多不同的合成生成的2D图像，每个都来自不同的可能的观察方向。 然后，将这些合成图像中的每一个进行特征提取处理，以提取图像中所示的登记特征的特征特征数据。 一旦对每个图像进行特征提取，当要执行注册时，通过将提取的特征集合中的每一个集合来处理实时2D图像，以尝试并识别哪个集合最佳地匹配2D中的注册特征 图片。 例如，在特征提取中使用广义霍夫变换的情况下，将R表应用于2D图像以获得各自的累积图像。 然后可以对累积图像进行排序，以识别在2D图像中以及从哪个视图方向示出哪个登记特征。 这给出了在2D图像中显示哪个登记特征所需的信息，以及平面内的位置和方向。 然后可以将该信息用作2D到3D注册过程的起点。

    Vista modulators for diagnosis and treatment of cancer
    9.
    发明授权
    Vista modulators for diagnosis and treatment of cancer 有权

    公开(公告)号：US11529416B2

    公开(公告)日：2022-12-20

    申请号：US16411488

    申请日：2019-05-14

    Applicant: KINGS COLLEGE LONDON ,  THE TRUSTEES OF DARTMOUTH COLLEGE

    Inventor： Randolph Noelle

    IPC: A61K35/17 ,  C07K14/705 ,  C12N15/62 ,  C12N5/10 ,  C12N15/12 ,  G01N33/53 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  A61K39/39 ,  A61K47/68 ,  A61K39/00 ,  A61K45/06 ,  C12N15/113

    Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

Patent Agency Ranking